Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development
JS Berry, Timothy J. Vreeland, D. K. Hale, DO Jackson, AF Trappey, J.M. Greene, MO Hardin, Garth S. Herbert, Guy Travis Clifton, GE Peoples · Journal of Cancer · 2017
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · article · 2017
Abstract
INTRODUCTION: Peptide vaccines offer anti-tumor efficacy with very low toxicity. However, repeat stimulation with an immunogenic peptide leads to activation induced cell death (AICD), decreasing efficacy. We engineered variants of an immunogenic peptide (E39) and tested their ability to induce a robust, sustainable immune response. METHODS: Multiple variants of E39 were created by exchanging 1 or 2 amino acids. We tested the PBMC proliferation, cytokine production and cytolytic activity induced by each variant peptide. RESULTS: AICD, while stimulation with E39' led to T-cell proliferation with less evidence of AICD, modest cytokine production and high CTL activity.
CONCLUSIONS: E39' appears to be the optimal variant of E39 for inducing effective long-term immunity.
Open the resolved locator · 10.7150/jca.16450
Metadata licence: OpenAlex metadata (CC0)